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A B S T R A C T
Extracellular amino acid (AA) withdrawal/restriction invokes an integrated stress response (ISR) that induces
global suppression of protein synthesis whilst allowing transcription and translation of a select group of genes,
whose protein products facilitate cellular adaptation to AA insufficiency. Transcriptional induction of the System
A/SNAT2 AA transporter represents a classic adaptation response and crucially depends upon activation of the
General Control Nonderepressible-2 kinase/Activating transcription factor 4 (GCN2/ATF4) pathway. However,
the ISR may also include additional signalling inputs operating in conjunction or independently of GCN2/ATF4
to upregulate SNAT2. Herein, we show that whilst pharmacological inhibition of MEK-ERK, mTORC1 and p38
MAP kinase signalling has no detectable effect on System A upregulation, inhibitors targeting GSK3 (e.g.
SB415286) caused significant repression of the SNAT2 adaptation response. Strikingly, the effects of SB415286
persist in cells in which GSK3α/β have been stably silenced indicating an off-target effect. We show that
SB415286 can also inhibit cyclin-dependent kinases (CDK) and that roscovitine and flavopiridol (two pan CDK
inhibitors) are effective repressors of the SNAT2 adaptive response. In particular, our work reveals that CDK7
activity is upregulated in AA-deprived cells in a GCN-2-dependent manner and that a potent and selective CDK7
inhibitor, THZ-1, not only attenuates the increase in ATF4 expression but blocks System A adaptation.
Importantly, the inhibitory effects of THZ-1 on System A adaptation are mitigated in cells expressing a dox-
ycycline-inducible drug-resistant form of CDK7. Our data identify CDK7 as a novel component of the ISR reg-
ulating System A adaptation in response to AA insufficiency.
1. Introduction
The solute carrier 38 (SLC38) transporter family comprises six
functionally characterised amino acid (AA) transporters from the eleven
members that have been identified in the human genome and notably
include two sub groups whose activities align with those classically
described as System A or System N [9]. The System A transporters in-
clude SNAT1, SNAT2 and SNAT4 (aka SLC38A1, SLC38A2 and
SLC38A4, respectively) and these mediate the sodium-dependent up-
take of short chain neutral AAs such as alanine, serine and threonine.
System A was functionally characterised by its ability to accept N-al-
kylated substrates such as α-(methyl-amino)isobutyric acid (MeAIB),
whereas, those of the System N family, which include SNAT3, SNAT5
and SNAT7 (aka SLC38A3, SLC38A5 and SLC38A7 respectively), do not
accept Me-AIB but show preference for AAs containing an extra ni-
trogen in their side chains (i.e. glutamine, asparagine and histidine) as
substrates and, moreover, exhibit tolerance for lithium as a sodium
substitute [26].
Whilst transporters of the System A sub group share significant se-
quence homology, it is widely established that SNAT2 (SLC38A2) is the
most ubiquitously expressed and, strikingly, one of the most extensively
regulated AA transporters to have been documented to date, possibly
reflecting its important contribution to cellular AA nutrition and to the
control of diverse cellular functions. SNAT2 expression/activity is, for
example, subject to both acute and chronic modulation by hormones
(e.g. glucocorticoids, estrogen, insulin) and growth factors
[2,20,24,55]. In tissues, such as the mammary gland, the transcrip-
tional upregulation of SNAT2 by 17β-estradiol may play a significant
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role in meeting the increased AA demand that facilitates differentiation
and proliferation of this tissue in preparation for lactation [55],
whereas, in skeletal muscle, recruitment of SNAT2 carriers from an
intracellular compartment to the plasma membrane and the attendant
increase in AA delivery in response to insulin may form part of the
anabolic effect that the hormone has upon muscle protein synthesis
[20,24]. SNAT2 can also be upregulated in cells subjected to hyper-
osmotic stress; a response designed to elevate cellular intake of organic
osmolytes (AAs) that helps establish an osmotic drive for water uptake
into cells to restore both intracellular volume and ionic strength
[6,10,36]. Crucially, the sodium coupled uptake of extracellular AAs
establishes an outwardly-directed concentration gradient of SNAT
substrates, which, if not immediately utilised for metabolic processes,
can leave the cell via tertiary exchange transporters, such as the leucine-
preferring (LAT1) carrier, that operates in parallel with SNAT2 in the
plasma membrane [5,21]. This SNAT2/LAT1 exchange coupling is
considered significant for intracellular leucine delivery given that this
essential AA serves to potently activate the mTORC1/S6K1 signalling
axis [33]. The mechanistic target of rapamycin complex 1 (mTORC1)
plays a pivotal role in the control of mRNA translation, cell growth/
metabolism and autophagy [50] and consequently factors affecting
SNAT2 expression/activity will indirectly impact on the regulation of
these key cellular processes by virtue of the changes that occur in
mTORC1 activity [47,54].
Whilst AA insufficiency, even of a single AA such as methionine or
leucine, exerts a profound suppressive effect on global mRNA transla-
tion [37], the expression and translation of a sub-set of genes that allow
cellular adaptation to changes in environmental nutrient supply is up-
regulated [25]. A key mediator of this amino acid response (AAR) is the
general control nonderepressible-2 kinase (GCN2), which, in response
to AA insufficiency, is activated by the binding of uncharged tRNAs that
result in eIF2α phosphorylation and a reduction in global mRNA
translation [11]. Paradoxically, however, the translation of specific
mammalian mRNA transcripts such as those encoding activating tran-
scription factor 4 (ATF4), or enzymes involved in AA biosynthesis (e.g.
asparagine synthase), AA transport (e.g. SNAT2) and that of the ATF4-
dependent transcription factor CHOP (C/EBP Homologous Protein) is
elevated [27,35]. The transcriptional increase in SNAT2 expression is
dependent upon an AA responsive domain in the first intron of the
SLC38A2 gene activated by ATF4 [43]. However, for some of these
targets, such as SNAT2, the adaptive increase in expression/function is
also accompanied by enhanced protein stabilization via a process that
involves its reduced ubiquitination and degradation [23]. Moreover, in
the case of SNAT2, the extracellular presence and/or binding of sodium
also appears to be a requisite in supporting the genomic increase in
SNAT2 expression and its enhanced protein stability in response to AA
insufficiency [19]. This latter observation implies that, in addition to
the GCN2/ATF4 pathway, additional mechanisms are likely to con-
tribute to the integrated stress adaptation response. Indeed, the notion
that additional signalling inputs may form part of the AAR is supported
by data showing that in HEK293T and HepG2 cells the upregulation of
the early growth response-1 gene induced by either AA deprivation or
endoplasmic reticulum (ER) stress is independent of the GCN2/ATF4
pathway and instead involves activation of MEK-ERK signalling [51].
ER stress has also been shown to promote induction of SNAT2 [42] and
CHOP and, at least in the case of the latter, this induction is mediated
via an ATF-4 independent mechanism that can be repressed by in-
hibitors of Glycogen Synthase Kinase-3 (GSK3) [38]. Precisely how
GSK3 regulates ER-induced CHOP expression is currently unclear, and
whether it or MEK-ERK signalling form part of the AAR underpinning
adaptive changes in SNAT2 expression/activity remains currently un-
known.
In the current investigation we show that whilst inhibition of MEK-
ERK, mTORC1 and p38 MAP kinase signalling have no impact on the
adaptive increase in SNAT2 activity induced by AA insufficiency, two
structurally unrelated GSK3 inhibitors significantly blunt the SNAT2
response to AA withdrawal. Intriguingly, however, the repressive action
of GSK3 inhibitors on SNAT2 adaptation persists in cells in which
GSK3α/β are substantially depleted by shRNA indicating that the
pharmacological effects of these inhibitors most likely represent an off-
target effect. Our analysis reveals that this off-target effect is most likely
mediated via cyclin-dependent kinases (CDK) and in particular CDK7,
which we identify as a novel AA regulated kinase. Here we demonstrate
that a potent and selective inhibitor of CDK7 attenuates the SNAT2
adaptation response and that this repressive action can be mitigated in
cells expressing a doxycycline-inducible drug-resistant form of CDK7.
2. Materials and methods
2.1. Reagents
α-MEM (α-minimal essential medium), DMEM (Dulbecco's mod-
ified Eagle's medium), OPTI-MEM, Lipofectamine 2000 and anti-
biotic/antimycotic solution were from Invitrogen (Carlsbad, CA).
EBSS was obtained from Sigma-Aldrich (St Louis, MO). FBS was
purchased from BioSera (France). Restriction enzymes and other
DNA-modifying enzymes were purchased from either New England
Biolabs (Beverley, MA) or Roche Diagnostics (Burgess Hill, UK).
Olignucleotides were purchased from the University of Dundee Oligo
Synthesis Service (University of Dundee). Anti-Slc38a2 (SNAT2)
antibody was from MBL, anti-α-subunit Na/K-ATPase antibody was
from the Developmental Studies Hybridoma Bank (University of
Iowa), anti-β actin, anti-GAPDH and anti-Flag antibodies were from
Sigma-Aldrich, anti-V5 and Alexa-Fluor488 anti-mouse antibodies
were from Invitrogen. Antibodies against GSK3α/β, CDK5, p35,
CDK7 and CDK9 were purchased from Santa Cruz Biotechnology
(Dallas, TX). HRP-conjugated anti-mouse and anti-rabbit secondary
antibodies were purchased from Cell Signaling Technologies
(Beverley, MA). THZ-1 was from MedChemExpress (Sweden) and BS-
181 was purchased from Cayman Chemical (Ann Arbor, MI). THZ-
531 was a kind gift from Dr. Nathaneal Gray (Dana-Farber Cancer
Institute, Harvard Medical School). Go Taq DNA polymerase, deox-
yribonucleotide phosphates (dNTPs) and Moloney Murine Leukemia
Virus (M-MLV) reverse transcriptase were purchased from Promega
(Madison, WI). [32P]-ATP, [14C]-MeAIB and protein G-sepharose
were from GE Healthcare (Chicago, IL). Cycloheximide, ATF4 and
tubulin antibodies were purchased from Abcam (Cambridge, UK).
PD098059, SB415286, SB216763 and rapamycin were purchased
from Tocris Biosciences (Abingdon, UK). Roscovitine and flavopir-
idol were purchased from Santa Cruz Biotechnology. All other re-
agents were purchased from Sigma-Aldrich or VWR unless stated
otherwise.
2.2. Cell culture
L6 rat skeletal muscle cells were grown as described previously in α-
MEM containing 2% (v/v) FBS [18]. Experiments were carried out at
the myotube stage, typically 7 days post-seeding. The generation of a
stable GSK3α/β double knockdown L6 cell line and the pC3luc L6 cell
line have been described previously [23,53]. HeLa S3 cells stably ex-
pressing the doxycycline-inducible wild type or drug-resistant Flag-
CDK7 C312S construct or the empty vector [29] were kindly provided
by Dr. Nathanael Gray (Harvard Medical School, Boston). Hela S3 cells
were plated in DMEM/ 10% FBS/ 1% p/s medium supplemented with
1mg/ml G418 and 2 μg/ml puromycin. When cells were 80% confluent,
2 μg/ml doxycycline was added for 24 h. Cells were used for AA uptake
studies or harvested and lysates probed with an anti-C-terminal CDK7
(SCBT sc-365075) and anti-FLAG antibodies. Human embryonic kidney
(HEK) 293T cells, Ad293 cells and HeLa cells were maintained in
DMEM containing 10% (v/v) FBS. Amino acid deprivation was carried
out by cell incubation in EBSS. Amino acid resupply was carried out by
incubation in EBSS containing a complete mix of amino acids at plasma
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physiological concentrations. Pharmacological compounds were added
as described in the text and figure legends.
2.3. SDS-PAGE and immunoblotting
Cells were incubated and treated as described in the text and figure
legends. After treatment cells were washed twice in ice-cold PBS and
then lysed as described previously or used for preparation of total cell
membranes [18]. Protein concentrations in final lysates and membrane
preparations were determined using the Bradford method [7]. Cell ly-
sates and membrane preparations were separated using SDS-PAGE,
transferred onto PVDF membrane (Millipore) and immunoblotted with
the appropriate antibodies as described in the text and figure legends
followed by incubation with the appropriate horseradish peroxidase
(HRP)-conjugated anti IgG antibody. Proteins were detected using ECL
exposure to autoradiographic film (Konica Minolta (Tokyo, Japan)).
Quantification of immunoblots was carried out using Image J software
(NIH).
2.4. Cloning into adenoviral expression vector and generation of adenoviral
particles
Adenoviral constructs were generated using the AdEasy Adenoviral
Vector System (Agilent). Rat CDK5, CDK7, CDK9 and p35 sequences
were cloned into pShuttleCMV at the NotI and either XhoI or EcoRV
restriction sites using the oligos described in Table 1. A C-terminal V5
tag was introduced for the CDKs and a C-terminal FLAG tag for p35.
Site-directed mutagenesis to generate dominant negative (DN) mutants
was carried out using the QuikChange method and the oligos described
in Table 1. Plasmids were either transfected directly into HEK293T cells
as described below or used to generate adenoviral vectors as follows.
Plasmids were digested with PmeI and purified using phenol/chloro-
form extraction followed by isopropanol precipitation. 50 μg linearised
vector was transformed into BJ5183 E. coli cells that had previously
been transformed with pAdEasy vector and rendered competent again
by treatment with calcium chloride. Plasmids were prepared from
smaller recombinant colonies and transformed back into E. coli XL-Blue
cells and plasmids prepared again. Recombination was confirmed by
restriction digest analysis with PacI. To generate adenovirus particles
pShuttleCMV vectors were digested with PacI and purified using the
phenol/chloroform method and isopropanol precipitation. 4 μg di-
gested plasmid was transfected into a 25 cm2 flask of Ad293 using 20 μl
Lipofectamine 2000 in OPTI-MEM. Transfections were carried out for
4 h at 37 °C then the culture medium replaced with complete medium.
Cells were incubated for 7 days then washed in PBS and scraped into
1ml PBS. Cell suspensions were freeze-thawed 4 times then centrifuged
at 1000 rpm for 5min. The supernatant was collected and used to infect
a fresh 25cm2 flask of Ad293. Adenovirus was harvested when ap-
proximately 50% of the cells were detached from the flask surface
(7–10 days) by scraping and freeze-thawing as before. High-titre viral
stocks were generated by repeating the harvesting/infection protocol
twice more. The amount of virus needed for transductions was de-
termined using immunofluorescence as follows. L6 cells were seeded
onto glass coverslips in multi-well plates and transduced with in-
creasing amounts of adenovirus preparation at 3 days post-seeding by
washing in serum-free medium and incubating with the virus in a
minimal volume of medium for 2 h before replacing the medium with
complete medium. Cells were fixed in 4% paraformaldehyde at the
myotube stage and immunofluorescence carried out as described pre-
viously [53] using either V5 or FLAG antibodies at the concentrations
recommended by the manufacturer and anti-mouse Alexa-Fluor488
secondary antibody. Fluorescence microscopy was used to determine
the dose of virus required to ensure that> 90% cells were expressing
the recombinant protein. L6 cells used in experiments were transduced
in a similar manner as those for immunofluorescence using the dose of
virus found to transduce>90% of the cells.
2.5. Amino acid uptake assay
Methyl-aminoisobutyric (MeAIB) acid uptake assays were per-
formed as described previously [18,23]. L6 myotubes were seeded in 12
well plates and transduced at 3 days post-seeding with an amount of
virus found to lead to expression of the relevant protein in over 90% of
the cells as determined in the methods above. MeAIB uptake assays
were carried out when the cells reached the myotube stage (approxi-
mately 7–8 days post-seeding). HEK293T cells were transfected with
the relevant plasmids the day after seeding. For each well 0 .5μg
plasmid was combined with 25 μg polyethyleneimine (PEI) in 0 .5ml
serum-free medium and incubated at RT for 30min. The medium on the
cells was changed to serum-free medium and the transfection mix
added. Cells were incubated for 4 h at 37 °C then the medium replaced
with complete medium and the incubation continued. MeAIB uptake
assays were carried out 18–24 h later using [14C] Me-AIB tracer.
2.6. Transfection of HEK 293T cells for activity assays
HEK 293T cells were seeded in 10 cm dishes. 5 μg of pShuttleCMV/
CDK plasmid was mixed with 500 μl serum-free medium and 25 μg PEI
and incubated at RT for 30min. The medium on the cells was replaced
with serum-free medium and the transfection mix added. Cells were
incubated for 4 h at 37 °C then the medium replaced with complete
medium. Cells were lysed the following day as described above and
used for activity assays.
2.7. Kinase activity assays
GSK3β kinase activity assays have been described previously [53].
pShuttleCMV/CDK7-V5 was transfected into the HEK293T and lysates
prepared as described above. Recombinant V5-tagged CDK7 was im-
munoprecipitated from 1mg lysate for 2 h at 4 °C using protein G-se-
pharose beads that had previously been conjugated to V5 antibody at a
ratio of 1 μl antibody per 20 μl slurry. Antibody-bead complexes were
washed twice in lysis buffer containing an additional 0 .5M sodium
chloride and then twice in CDK7 wash buffer (20mM Tris pH 7.5,
7 .5mM MgCl2). Beads were resuspended to a final volume of 25 μl in
CDK7 assay buffer (20mM Tris pH 7.5, 7.5 mMMgCl2, 0 .2μg/μl histone
H1, 10 μM non-radiolabelled ATP and 5 μCi [32P] ATP) and incubated
shaking for 1 h at 37 °C. 15 μl of reaction volume was spotted onto p81
filter paper. The filter papers were allowed to dry and then washed 3
times in 1% phosphoric acid and then once in acetone. Filter papers
were dried and [32P] ATP incorporation measured using a Beckman LS
6000IC scintillation counter.
pShuttleCMV/CDK9-V5 was transfected into the HEK293T and ly-
sates prepared as described above. Recombinant V5-tagged CDK9 was
immunoprecipitated from 1mg lysate in a similar manner as for CDK7.
Antibody bead complexes were washed twice in lysis buffer containing
an additional 0 .5M sodium chloride and then twice in CDK9 wash
buffer (50mM Tris pH 7.4, 0.1 mM EDTA, 10mM magnesium acetate).
Beads were resuspended to a final volume of 25 μl in CDK9 assay buffer
(50mM Tris pH 7.4, 0.1mM EDTA, 10mM magnesium acetate, 10mM
DTT, 1mg/ml BSA, 0 .3mM CDK9 substrate (YSPTSPSYSPTSPSYSPTS-
PSKKK) (MRC Reagents and Services, University of Dundee), 5 μM non-
radiolabelled ATP and 5 μCi [32P] ATP) and incubated shaking for 1 h at
22 °C. 15 μl of reaction volume was spotted onto p81 filter papers and
the filter papers washed and counted as above.
pShuttleCMV/CDK5-V5 and pShuttleCMV/p35-FLAG were co-
transfected into the HEK293T and lysates prepared as described above.
Recombinant V5-tagged CDK5 was immunoprecipitated from 0 .5mg
lysate for 2 h at 4 °C using protein G-sepharose beads that had pre-
viously been conjugated to V5 antibody at a ratio of 1 μl antibody per
20 μl slurry. Endogenous CDK5 was immunoprecipitated from lysates
generated from L6 myotubes using protein G-sepharose beads that had
previously been conjugated to either V5 antibody (1 μl per 20 μl slurry)
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or CDK5 antibody (5 μg per 20 μl slurry). Antibody-bead complexes
were washed twice in lysis buffer containing an additional 0 .5M so-
dium chloride then twice in CDK5 wash buffer (20mM Tris pH 7.4,
10mM MgCl2, 1mM EDTA, 1mM NaF, 0 .1mM Na2VO3). Beads were
resuspended in 50 μl CDK5 assay buffer (20mM Tris pH 7.4, 10mM
MgCl2, 1mM EDTA, 1mM NaF, 0 .1mM Na2VO3, 0 .2μg/μl histone H1,
0 .1mM non-radiolabelled ATP and 5 μCi [32P] ATP) and incubated
shaking for 30min at 30 °C. 25 μl of reaction was spotted onto p81 filter
paper. The filter papers were dried then washed 3 times in 0.75%
phosphoric acid and once in acetone before being dried and counted as
above.
2.8. RNA extraction, cDNA synthesis and real-time PCR
RNA was extracted from cells using TriReagent according to the
manufacturer's instructions. First-strand cDNA was synthesised from
Table 1
Oligos used for cloning (A), real-time PCR (B) and generation of shRNA lentiviral constructs (C).
(A) Cloning oligos
Oligo
Sequence (5′-3′)
Top line: Forward; Bottom line: Reverse
Cloning
CDK5 ATCGACGCGGCCGCGCCACCATGCAGAAATACGAGAAACTG
ATCGACCTCGAGCTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCCGGGGGACAGAAGTCAGAG
P35 ATCGACGCGGCCGCGCCACCATGGGCACGGTGCTGTCCCTG
ATCGACCTCGAGCTACTTGTCATCGTCGTCCTTGTAGTCCCGATCGAGCCCCAGGAG
CDK7 ATCGACGCGGCCGCGCCACCATGGCTGTGGACGTGAAATC
ATCGACGATATCCTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCAAAAATTAGCTTCTTGGGC
CDK9 ATCGACGCGGCCGCGCCACCATGGCCAAGCAGTACGACTC
ATCGACGATATCCTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCGAAGACACGTTCAAATTC
Site-directed mutagenesis
CDK5 D144N GAACTGAAATTGGCTAATTTTGGCCTGGCCCGA
TCGGGCCAGGCCAAAATTAGCCAATTTCAGTTC
CDK7 D155A TTCTGAAACTGGCAGCTTTTGGCCTGGCCAA
TTGGCCAGGCCAAAAGCTGCCAGTTTCAGAA
CDK9 D167A TCCTAAAGCTGGCAGCTTTTGGGCTGGCTCG
CGAGCCAGCCCAAAAGCTGCCAGCTTTAGGA
(B) qPCR oligos
Oligo
Sequence (5′-3′)
Top line: Forward; Bottom line: Reverse
SNAT2 (rat) ACCCTCACTGTCCCCGTCGTC
AAGGCCAGGATCGTCACAGTAATG
SNAT2 (human) GTGTTAATGGCTGTGACCCTGAC
GAGACTATGACGCCACCAACTGA
CDK5 (rat) TGGGGAAGGCACCTACGGAACT
GAGGGCTGAACTTGGCACACC
CHOP (rat) ACGTCGATCATACCATGTTGAAG
GGTTTCTGCTTTCAGGTGTGG
CHOP (human) AATGGGGGTACCTATGTTTCAC
TCAGTCAGCCAAGCCAGAGA
ATF3 (human) AGACGGAGTGCCTGCAGAAAGAGT
GTGGGCCGATGAAGGTTGAGC
EGR1 (human) CTGACCGCAGAGTCTTTTCCT
GCCACTGACCAAGCTGAAGA
ATF4 (human) AACCGACAAAGACACCTTCG
ACCCATGAGGTTTGAAGTGC
GAPDH (rat/human) TGGAAAGCTGTGGCGTGAT
GCTTCACCACCTTCTTGAT
(C) shRNA oligos
Oligo
Sequence (5′-3′)
Top line: Forward; Bottom line: Reverse
shRNA
148
CCGGCGGGAGATCTGTCTACTCAAACTCGAGTTTGAGTAGACAGATCTCCCGTTTTTG
AATTCAAAAACGGGAGATCTGTCTACTCAAACTCGAGTTTGAGTAGACAGATCTCCCG
shRNA
298
CCGGCCTGAGATTGTGAAGTCACTCCTCGAGGAGTGACTTCACAATCTCAGGTTTTTG
AATTCAAAAACCTGAGATTGTGAAGTCACTCCTCGAGGAGTGACTTCACAATCTCAGG
shRNA
529
CCGGAAGCTGTACTCCACGTCCATCCTCGAGGATGGACGTGGAGTACAGCTTTTTTTG
AATTCAAAAAAAGCTGTACTCCACGTCCATCCTCGAGGATGGACGTGGAGTACAGCTT
shRNA
723
CCGGGTACCCAGCTACAACATCCTTCTCGAGAAGGATGTTGTAGCTGGGTACTTTTTG
AATTCAAAAAGTACCCAGCTACAACATCCTTCTCGAGAAGGATGTTGTAGCTGGGTAC
shRNA
795
CCGGCCTGTTGAAGTGTAACCCAGTCTCGAGACTGGGTTACACTTCAACAGGTTTTTG
AATTCAAAAACCTGTTGAAGTGTAACCCAGTCTCGAGACTGGGTTACACTTCAACAGG
For (C) each hairpin consisted of a 21-nucleotide sense sequence, a short hairpin sequence (CTCGAG), a 21-nucleotide antisense sequence, and five
thymidines (a stop signal for RNA polymerase). Sense and antisense strands are in bold, hairpin loop is indicated by italics.
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1 μg of total RNA using oligo(dT)15 primers and MMLV reverse tran-
scriptase according to the manufacturer's instructions. Real-time
quantitative PCR was performed using a StepOne Plus real-time ther-
mocycler (Applied Biosystems), SYBR Green JumpStart kit
(Sigma–Aldrich) and primers targeting SNAT2, CDK5, CHOP, ATF3,
ATF4, EGR1 and GAPDH (Table 1). PCR conditions were as follows:
initial denaturation at 95 °C for 2min followed by 40 cycles of 95 °C for
15 s, 55 °C for 15 s and extension at 68 °C for 30 s. The ratio of SNAT2,
ATF3, ATF4, EGR1 and CHOP expression to GAPDH mRNA expression
was calculated using a method described previously [46].
2.9. Generation of shRNA-containing lentivirus and production of stable cell
lines
Stable L6 CDK5 knockdown cell lines were generated in a similar
manner to that described previously [34,53] using the pLKO.1-puro
vector and the oligos detailed in Table 1. The control hairpin sequence
was that used previously. Stable cell lines were established using early
passage cells and, once established, were only used for a maximum of
five passages. Knockdown efficiency of CDK5 was assessed using wes-
tern blotting and real-time PCR.
2.10. Statistical analyses
For multiple comparisons, statistical analysis was performed using
one-way ANOVA. For individual comparisons, statistical analysis was
performed using Student's t-test. Data analysis was performed using
GraphPad Prism software and considered statistically significant at
P < 0.05.
3. Results and discussion
3.1. Effects of GCN2, MEK/ERK and GSK3 inhibition on System A/SNAT2
activity/expression in response to amino acid deprivation
The adaptive upregulation of System A/SNAT2 transport in re-
sponse to cellular amino acid insufficiency is a remarkably well pre-
served phenomenon [21]. Fig. 1A shows that L6 myotubes subjected to
extracellular AA withdrawal for 6 h exhibit a 4-fold increase in Me-AIB
uptake; a paradigm non-metabolisable System A substrate. Consistent
with the idea that the adaptive response is primarily dependent on
increased expression and translation of SNAT2 mRNA and that this
requires activation of GCN2, the observed increase in Me-AIB uptake
was significantly blunted by A-92 (a GCN2 inhibitor, [8]) and cyclo-
heximide (a eukaryotic protein synthesis inhibitor) when they were
present during the AA withdrawal period (Fig. 1A and B). Fig. 1A lower
panel shows that under these circumstances, AA deprivation induces
phosphorylation of eIF2α, the primary GCN2 target, and that this is
suppressed by the presence of A-92.
In order to garner some insight into whether MAP kinases (MEK/
Fig. 1. Effects of protein synthesis and kinase inhibitors on System A/SNAT2 adaptation in response to AA withdrawal.
(A) L6 myotubes were deprived of amino acids (−) or not (+) for 6 h in the presence/absence of 10 μM A-92 (GCN2 inhibitor). Cells were either used to assay Me-AIB
uptake (upper panel) or subjected to western blotting using the antibodies shown. (B). L6 myotubes were deprived of amino acids (−) or not (+) for 6 h in the
presence/absence of 5 μg/ml cyclohexamide (protein synthesis inhibitor) then the rate of Me-AIB uptake assayed. (C) L6 myotubes were deprived of amino acids (−)
or not (+) for 6 h in the presence/absence of 10 μM unlabelled Me-AIB, 50 μM PD098059 (MEK inhibitor), 10 μM SB203580 (p38 MAPK inhibitor), 100 nM
rapamycin (mTORC1 inhibitor), 50 μM SB415286 or 5 μM SB216763 (GSK3 inhibitors) and 10 μM A-92 prior to analysis of Me-AIB uptake. The adaptive increase in
System A transport induced by AA withdrawal in myotubes in the absence of any inhibitors was assigned a value of 100% (vehicle control). The adaptive increase in
System A transport measured in the presence of Me-AIB or the different kinase inhibitors was then expressed relative to that of the vehicle control condition. (D) L6
myotubes were incubated with or without amino acids for 6 h in the presence of SB216763 or SB415286 before being assayed for Me-AIB uptake. (E) L6 myotubes
were incubated for 6 h in the presence/absence of amino acids and 50 μM SB415286. Total membranes were prepared, subjected to SDS-PAGE and immunoblotted
using the antibodies against SNAT2 and the alpha1 subunit of the Na,K-ATPase. Blots are representative of at least 3 independent experiments. Quantified values are
presented as the mean ± SEM. *P < 0.05.
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ERK and p38 MAP kinases) and/or GSK3 may support the adaptive
increase in System A we subsequently investigated what impact tar-
geting these kinases with pharmacological inhibitors would have on the
adaptive response. As a positive inhibitory control, we have shown
previously that the System A adaptation response is critically dependent
upon substrate availability/carrier occupancy [23]. In line with this,
the adaptive increase in System A transport in L6 myotubes maintained
in AA-free EBSS, but supplemented with 2mM Me-AIB alone was
markedly reduced (Fig. 1C). Consistent with the data presented in
Fig. 1A, the presence of the GCN2 inhibitor (A-92) during the AA
withdrawal period suppressed the adaptive increase in System A
transport. In contrast, neither PD098059 nor SB203580 (which re-
spectively target MEK/ERK and p38 MAP kinases) had any detectable
effect upon the adaptive increase in AA-deprived myotubes. It should be
stressed that the efficacy of both inhibitors, in terms of suppressing the
insulin- or stress-induced activation of these kinases, was validated in
parallel experiments (data not shown). Rapamycin, which inhibits the
AA-regulated mTORC1/S6K1 signalling axis [45], was also without
effect, whereas, both SB415286 and SB216763 (two well established
but structurally distinct GSK3 inhibitors [12]) significantly blunted the
adaptive increase in System A-mediated Me-AIB uptake in a dose de-
pendent manner (Fig. 1C and D). The inhibition in transport activity
caused by SB415286 was associated with a reduction in the cellular
SNAT2 abundance that is normally seen in AA-deprived cells (Fig. 1E).
3.2. Effects of GSK3α/β gene silencing on the SNAT2 adaptive response
The data presented in Fig. 1C–E implicated GSK3 in the adaptive
regulation of SNAT2. To explore the involvement of this kinase further
we assessed whether its activity was modulated in AA-deprived cells.
Fig. 2A shows that there was no discernible change in GSK3 activity in
L6 myotubes when these were AA-deprived for up to 1 h. GSK3 is
constitutively active in most mammalian cells and it is plausible that
whilst AA availability has no direct impact on the kinase that its activity
Fig. 2. Effects of AA withdrawal on GSK3 α/β ac-
tivity and effects of GSK3 α/β silencing on System A/
SNAT2 adaptation in L6 myotubes.
L6 myotubes were acutely deprived of amino acids
(AA-) for the times indicated prior to assaying total
GSK3 (α/β) activity (A). Control and GSK3 silenced
cells were incubated in the presence/absence of
amino acids for 6 h and used to prepare total cell
lysates (B), total membranes (C) or assay Me-AIB
uptake (D). Blots showing GSK3 and actin (loading
control) are representative of at least 3 individual
experiments. Quantified values are presented as the
mean ± S.E.M. *P < 0.05. NS, not significant.
Fig. 3. Effects of roscovitine and SB415286 on CDK5 and GSK3β activity in L6
myotubes.
Wild-type L6 myotubes were incubated in EBSS containing amino acid mix at
plasma physiological concentrations for 6 h in the presence/absence of 50 μM
SB415286 or 30 μM roscovitine as indicated. Cell lysates were prepared and
either 500 μg or 100 μg subjected to immunoprecipitation with CDK5 or GSKβ
antibodies respectively. Kinase activity assays were carried out using histone H1
or phospho-GS peptide respectively as substrates. Activities are presented as the
mean ± S.E.M (n=3).
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is an integral part of the AAR. To test this proposition we utilised len-
tivirus-based shRNA technology to generate L6 myotubes exhibiting
stable knockdown of both GSK3α and GSK3β [53]. In two separate
clonal L6 cell lines (sh428/1225 and sh493/1225) we were able to get
substantial depletion (> 90%) of both GSK3 isoforms (Fig. 2B). Sur-
prisingly, however, despite this significant depletion in GSK3 expres-
sion, subjecting GSK3-silenced cells to AA deprivation for 6 h did not
abate the adaptive increase in SNAT2 protein abundance (Fig. 2C) nor
the associated increase in functional transport activity that remained
sensitive to inhibition by SB415286 (Fig. 2D). These latter observations
imply that it is highly unlikely that GSK3 is a component of the AAR
and that the effects of SB415286 (and SB26763) most likely represent
an off-target effect. Consistent with this idea, there is evidence that
SB415286 and SB26763 can also inhibit members of the cyclin-de-
pendent kinase (CDK) family in vitro, which are well known targets of
the olomoucine derivative, roscovitine [4]. To test the possibility of an
off-target effect we assayed the sensitivity of CDK5 (as a representative
member of the CDK family) and GSK3β to SB415286 and roscovitine.
Fig. 3 shows that immunoprecipitable CDK5 activity from L6 myotubes
was reduced when assayed in the presence of both roscovitine and
SB415286 using an in vitro-based kinase assay. In contrast, roscovitine
had no detectable effect upon GSK3β activity.
3.3. Effects of CDK inhibitors on the System A/SNAT2 adaptive response
Having established that SB416286 could inhibit a CDK family
member in vitro we subsequently explored what effect roscovitine and
flavopiridol (another pan CDK-inhibitor) may have upon the System A/
SNAT2 adaptive response in L6 muscle cells. Fig. 4A and B (upper pa-
nels) shows that both roscovitine and flavopiridol were as effective as
SB415286 in reducing the adaptive increase in Me-AIB uptake in L6
myotubes that is induced by a 4 h period of AA deprivation and that this
loss in functional transport activity was also associated with a marked
reduction in both basal and SNAT2 mRNA abundance. The observed
sensitivity of the AAR to roscovitine and flavopiridol was not restricted
to L6 myotubes as the effect of both CDK inhibitors on the AAR was also
seen in the human cervical cancer cell line, HeLa (Fig. 4A and B; lower
panels). To further substantiate that CDK inhibition was associated with
a reduction in the AAR invoking an increase in SNAT2 gene tran-
scription we utilised L6 cells that had been stably transfected with a
pcDNA3 luciferase reporter construct, driven by the SNAT2 promoter
that included the first intronic element containing the tripartite AAR
domain [23]. Fig. 4C shows AA deprivation enhances luciferase ex-
pression, but that this was absent when cells were exposed to SB415286
or inhibitors targeting the CDK family during the AA withdrawal
period. Furthermore, consistent with the data shown in Fig. 4A, the
increase in SNAT2 protein induced by AA deprivation in L6 myotubes
was also repressed by roscovitine (Fig. 4D).
3.4. CDK inhibitors suppress expression of ATF4, CHOP and ATF3
The adaptive increase in SNAT2 gene expression is, in part,
Fig. 4. Effects of SB415286, roscovitine and flavopiridol on System A/SNAT2 adaptation in response to AA insufficiency in L6 myotubes and HeLa cells.
(A) Wildtype L6 myotubes and HeLa cells were deprived of amino acids (−) or not (+) for 6 h in the presence/absence of 50 μM SB415286, 30 μM roscovitine or
500 nM flavopiridol as indicated. Following incubation the rate of MeAIB uptake was assayed. (B) Wildtype L6 myotubes and HeLa cells were deprived of amino acids
(−) or not (+) for 6 h in the presence of 50 μM SB415286, 30 μM roscovitine or 500 nM flavopiridol as indicated. RNA was isolated, cDNA synthesised and
expression of SNAT2 mRNA was determined by quantitative PCR analysis. (C) L6 myotubes stably expressing a pcDNA3 luciferase reporter construct were deprived of
amino acids (−) or not (+) for 8 h in the presence/absence of 50 μM SB415286, 30 μM roscovitine or 500 nM flavopiridol as indicated and luciferase expression
subsequently assayed. Quantified values in all panels are presented as the mean ± S.E.M. (n=3). (D) Wild-type L6 cells were deprived of amino acids (−) or not
(+) for 6 h in the presence/absence of 50 μM SB415286 or 30 μM roscovitine then total membranes prepared and subjected to SDS-PAGE followed by im-
munoblotting for SNAT2 and the α1 subunit of Na/K ATPase as a loading control. Blots are representative of at least three independent experiments. Asterisk
represents a significant difference between the indicated bars (P < 0.05).
C. Stretton, et al. BBA - Molecular Cell Research 1866 (2019) 978–991
984
dependent upon ATF4 [27]; a transcription factor whose expression,
like that of the SNAT2 gene, is upregulated in response to AA deficiency
and, which, in addition to SNAT2, supports the upregulation of genes
such as CHOP and ATF3 that form as part of the AAR. Given that pan
CDK inhibitors blocked SNAT2/System A adaptation and some CDKs
have important roles in transcriptional control [40] we subsequently
assessed what effect these inhibitors have on ATF4 and some of its
transcriptional targets that are upregulated by the AAR. In line with
previous studies, Fig. 5A shows that L6 myotubes or HeLa cells sub-
jected to a 6 h period of AA deprivation exhibit a robust increase in
ATF4 protein abundance, which, strikingly, was not observed when
cells were AA-deprived in the presence of SB415286, roscovitine or
flavopiridol. Consistent with this latter observation, the expression of
ATF4, CHOP and ATF3, whose gene expression is also induced by AA
withdrawal, was suppressed significantly in cells exposed to the in-
hibitors used (Fig. 5B).
3.5. Effects of expressing dominant negative forms of CDK5, CDK7 and
CDK9 on the System A adaptation response
Roscovitine and flavopiridol are pan-CDK inhibitors and conse-
quently do not allow discrimination of which CDK isoform(s) may
participate in the AAR. However, in addition to their critical role in the
cell cycle, it is widely accepted that some members of the CDK family
have other key cellular functions [13,15]. For example, CDK5 has little
involvement in the cell cycle but has been implicated in the regulation
of cytoskeletal elements, synaptic function and membrane transport
events (see review [13]), whereas CDK7 and CDK9 belong to the
transcriptional sub-family of CDKs [15]. Since the inhibitory effects of
roscovitine and flavopiridol on the AAR are evident in terminally dif-
ferentiated L6 myotubes (in which there is minimal cell cycle activity)
we reasoned that CDK5 and those influencing transcriptional control
(i.e. CDK7 and CDK9) may be good candidates for further investigation.
To test their possible involvement we explored what impact cellular
expression of V5-tagged dominant–interfering forms of CDK5 (D144N)
[14], CDK7 (D155A) [49] and CDK9 (D167A) [16] may have on the
adaptive response. Fig. 6A shows that unlike the respective wild-type
kinases, the dominant-inhibitory forms of CDK5, CDK7 and CDK9 all
lack catalytic activity when assessed in immunoprecipitates of the re-
spective V5-tagged kinases expressed in HEK293T cells. Subsequent
cellular expression of wild type CDK5 and CDK9 or their dominant-
interfering forms had no detectable impact on the adaptive increase in
Me-AIB uptake when assayed in cells that had been AA deprived for 6 h
(Fig. 6B). The lack of any CDK5 involvement in the AAR was further
validated using L6 myotubes in which CDK5 had been stably silenced
by> 90% using a shRNA-lentiviral based strategy (Fig. 7). Despite the
substantial reduction in CDK5 expression, the System A adaptive re-
sponse (assessed using Me-AIB uptake as a readout) was unaffected
when assayed in two separate L6 CDK5 knock-down clones and, as
such, the AAR remains sensitive to SB415286 and roscovitine in the
CDK5-silenced cell lines (Fig. 7). However, unlike cells expressing
CDK5-D144N or CDK9-D167A, the expression of CDK7-D155A in
HEK293T cells resulted in significant blunting of the adaptive response
supporting its potential involvement in the AAR (Fig. 6B). This latter
proposition was further supported by our finding that CDK7 activity
was elevated by nearly 4–5-fold when HEK293T cells were AA deprived
Fig. 5. Effects of SB415286, roscovitine and flavopiridol on ATF4 and ATF4-regulated genes in L6 myotubes and HeLa cells during AA insufficiency.
(A) L6 myotubes and HeLa cells were deprived of amino acids (−) or not (+) for 6 h in the presence/absence of 50 μM SB415286, 30 μM roscovitine or 500 nM
flavopiridol then the cells lysed and subjected to SDS-PAGE followed by immunoblotting with the indicated antibodies. Blots are representative of at least 3
independent experiments. (B) L6 myotubes or HeLa cells were deprived of amino acids (−) or not (+) for 6 h then RNA prepared from the cells, cDNA synthesised
and the expression of the indicated gene transcripts determined by quantitative PCR analysis. Data is presented as the mean ± S.E.M. (n= 3).
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for 6 h (Fig. 6C).
3.6. Targeted inhibition of CDK7 blunts the System A/SNAT2 adaptive
response
To further substantiate involvement of CDK7 in the AAR, we in-
vestigated the effects of THZ-1 and BS-181 (two highly selective CDK7
inhibitors with IC50 values of 3.2 and 21 nM, respectively [1,29]). In
line with the data presented in Fig. 1, subjecting HeLa cells to a 6 h
period of AA deprivation induced a significant increase in both SNAT2
mRNA abundance and Me-AIB uptake, neither of which was apparent in
cells treated with THZ-1 during the AA withdrawal period (Fig. 8A, B).
Likewise, the adaptive increase in System A transport was also re-
pressed by the structurally unrelated CDK7 inhibitor, BS-181 (Fig. 8B).
As indicated earlier, pan CDK inhibitors repress the increase in ATF4.
To confirm that such repression is indeed mediated by CDK7, analysis
of ATF4 protein in HeLa cells that had been AA-deprived in the absence
and presence of THZ-1 revealed that the increase in ATF4 was blocked
by CDK7 inhibition and, as anticipated, also under circumstances when
GCN2 was inhibited using A-92 (Fig. 8C). It is possible that the re-
pression we see in ATF4 protein in AA deprived cells in the presence of
pan CDK inhibitors (SB415286, roscovitine and flavopiridol, Fig. 5A)
and THZ-1 (Fig. 8C) may reflect an off-target effect on GCN2. To test
this possibility the effects of AA withdrawal on eIF2α phosphorylation
(taken as a readout of GCN2 activity) was determined in the presence of
A-92, roscovitine, SB415286 and THZ-1. Fig. 8D shows that AA depri-
vation induced ~2-fold increase in eIF2α phosphorylation, which was
unaffected by the presence of roscovitine, SB415286 or THZ-1 but lost
in cells exposed to the GCN2 inhibitor, A-92. Collectively, the data
presented in Fig. 8A–D indicate that the adaptive increase in SNAT2/
System A expression/activity is reliant not only upon the GCN2/ATF4
pathway, but that CDK7 is likely to play an important role in the
transcriptional upregulation of ATF4 target genes. To further test the
specificity and involvement of CDK7 in the AAR we assessed the ex-
pression of the early growth response gene (EGR1) whose activation in
response to AA deprivation is known to be independent of the GCN2-
ATF4 pathway, but dependent on MEK-ERK signalling [51]. Fig. 8E
shows that we observed a modest, but significant increase in EGR1
expression in AA deprived HeLa cells and that, as anticipated, this was
not inhibited by the presence of A-92, which, in fact, had a modest
stimulatory effect on EGR1 expression. It is noteworthy that previous
work utilising HepG2 cells stably expressing shRNA against GCN2 also
found that, relative to parental cells or those expressing a control
shRNA sequence, the AAR induced a much greater level of EGR1 ex-
pression [51]. Likewise, whilst THZ-1 had no inhibitory effect on EGR1
expression, it too augmented expression of the EGR1 gene. Since we
postulate that CDK7 activation by AA withdrawal is downstream of
GCN2, these observations might indicate that whilst CDK7 can promote
Fig. 6. Effects of overexpressing wild-type and dominant interfering mutants of CDK5, CDK7 and CDK9 upon System A adaptation and effects on AA withdrawal (AA-
) on CDK7 activity in HEK293T cells.
(A) HEK293T cells were transfected with 5 μg of the following vectors; pShuttleCMV/CDK5-WT, pShuttleCMV/CDK5-D144N, pShuttleCMV/p35-FLAG,
pShuttleCMV/CDK7-WT, pShuttleCMV/CDK7-D155A, pShuttleCMV/CDK9-WT and pShuttleCMV/CDK9-D167A as indicated. Cell lysates were prepared and the
over-expressed CDKs immunoprecipitated from either 500 μg (CDK5) or 1 mg (CDK7 and CDK9) lysate using antibody targeted to the V5 tag. Activity assays for
CDK5, CDK7 and CDK9 were carried out. Data is expressed as a relative change to the wild type kinase activity. (B) Cells were transduced with adenovirus expressing
either V5 tagged WT or DN forms of CDK5 (D144N), CDK7 (D155A) and CDK9 (D167A). 24 h post transfection cells were incubated in the presence/absence of amino
acids for 6 h prior to assaying Me-AIB uptake or (C) analysis of CDK7 activity in V5 immunoprecipitates. Data in all cases is presented as the mean ± S.E.M. (n=3).
Blots are representative of at least three independent experiments. NS, not significant
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expression of SNAT2 during the AAR it may also exert a repressive
effect on non-ATF4 regulated stress genes such as EGR1, which we can
alleviate by inhibition with THZ-1. The notion that some CDKs may
function as both positive and negative regulators of transcription is not
unprecedented [40].
3.7. Amino acid deprivation induces CDK7-mediated phosphorylation of the
CTD of RNA polymerase II
CDK7 forms a heterotrimeric complex with cyclin H and MAT1 and
functions not only as a CDK-activating kinase (CAK), but as a crucial
component of the general transcription factor TFIIH. A key physiolo-
gical target for the TFIIH/CDK7 complex is the C-terminal domain
(CTD) of the large subunit of RNA Polymerase II (RNAPII), which, in
eukaryotic cells, contains 52 repeats of a heptapeptide
(Y1S2P3T4S5P6S7) sequence [56]. CDK7 phosphorylates Ser5 in these
heptads within the CTD of RNA polymerase II (RNAPII) and this is
considered to facilitate RNAPII promoter escape and transitioning to
the elongation step of gene transcription [41]. Consistent with the in-
crease in CDK7 activity that we see in AA starved cells (Fig. 6C), AA
deprivation induced a time-dependent increase in Ser5-phosphorylation
of the Pol II CTD in HeLa cells (Fig. 9A). This phosphorylation was
abolished by cell treatment with THZ-1; a selective and potent CDK7
inhibitor, but intriguingly also by the GCN2 inhibitor, A-92, in both
HeLa cells and L6 myotubes (Fig. 9B and C). We currently do not know
how CDK7 activation is mechanistically linked to the AA withdrawal
stimulus, but the observation that A-92 suppresses phosphorylation of a
CDK7 target implies that GCN2 activation in AA-deprived cells is
somehow involved and that this event is upstream of CDK7. Since GCN2
activation promotes synthesis of basic-region leucine zipper DNA
binding proteins such as ATF4, and expression of the latter in AA de-
prived cells is impaired by THZ-1 (Fig. 8C), our findings would suggest
that CDK7 may potentially link GCN2 to control of ATF4 gene
expression, which then subsequently may help to regulate expression of
nutrient transporters such as SNAT2 as part of the AAR.
3.8. Expression of a doxycycline-inducible drug-resistant CDK7 mitigates
THZ-1 inhibition of the System A adaptive response
Recent studies have indicated that the exceptional sensitivity of
CDK7 to THZ-1 is due to the covalent interaction that the inhibitor
forms with Cys312, which traverses the ATP cleft in the kinase domain
resulting in its irreversible inhibition. Strikingly, replacing Cy312 with
a less nucleophilic amino acid (Ser), ablates the interaction with the
inhibitor and renders the kinase resistant to THZ-1 [29]. To test if the
observed loss in the adaptive upregulation of System A/SNAT2 that we
see in response to THZ-1 could be prevented we utilised HeLa S3 cells
expressing doxycycline-inducible Flag-tagged versions of the wild type
and CDK7-C312S mutant [29]. Using Flag antibodies, Fig. 10A (upper
panel) shows that 24 h of doxycycline treatment induces expression of
the wild-type (WT) and CDK7-C312S mutant kinases, whereas cells
transfected with the empty vector (EV, control) do not. The C-terminal
directed anti-CDK7 antibody can give rise to two immunoreactive bands
as previously noted [28], but identifies an additional band in doxycy-
cline-treated cells that correspond to the exogenously expressed FLAG-
tagged protein. Cells expressing the EV, WT and C312S vectors were
subsequently either maintained in buffer containing or lacking the
physiological AA mix for 6 h in the absence and presence of THZ-1 prior
to analysis of Me-AIB uptake. Fig. 10A (lower panel) shows that HeLa
S3 cells expressing the EV or WT CDK7 exhibit the adaptive increase in
System A transport upon AA deprivation, which, as anticipated, was
attenuated in cells treated with THZ-1. However, cells expressing the
drug resistant CDK7-C312S mutant retain a significant adaptive re-
sponse in the presence of THZ-1 despite the inhibitory effect this drug
has upon the endogenously expressed CDK7 protein. Whilst THZ-1 is a
potent CDK7 inhibitor, at high concentrations it can potentially target
Fig. 7. CDK5 shRNA silencing in L6 myotubes does
not affect System A adaptation in response to AA
insufficiency
L6 myotubes were stably transduced with lentiviral
vectors expressing different shRNAs targeting
murine CDK5. Cells were lysed, separated by SDS-
PAGE and immunoblotted using antibodies targeting
CDK5 and GPADH (A) or RNA isolated, cDNA syn-
thesised and CDK5 mRNA assayed by quantitative
PCR (B). Blots and bar graphs are representative of
three individual experiments. Stably transduced L6
myotubes were amino acids deprived for 6 h in the
presence/absence of 50 μM SB415286 or 30 μM ros-
covitine and MeAIB uptake assayed (C). Values are
mean ± SEM (n=3).
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Fig. 8. Effects of THZ-1, BS-181 and A-92 on SNAT2 mRNA expression, System A adaptation and ATF4 protein abundance in response to AA withdrawal in HeLa cells
HeLa cells were deprived of amino acids (−) or not (+) for 6 h in the presence or absence of 1 μM THZ-1 (A, B, C), 5 μM BS-181 (B) or 10 μM A-92 (C) as indicated.
Following cell treatment, expression of SNAT2 mRNA was determined by quantitative PCR analysis of isolated RNA (A). Alternatively, Me-AIB uptake was measured
following the incubation period (B). ATF4 protein abundance was determined by subjecting resulting cell lysates to SDS-PAGE and then immunoblotting using anti-
ATF4 and anti-actin (used as loading control) antibodies as shown (C). Quantified values are presented as the mean ± S.E.M. (n= 3). *, P < 0.05. NS, not
significant.
Fig. 9. Effects of AA withdrawal, THZ-1 and A-92 on Pol II Ser5 phosphorylation in HeLa cells.
HeLa cells were deprived of amino acids (−) for the time periods shown (A). In addition, HeLa cells (B) or L6 myotubes (C) were deprived of amino acids (−) or not
(+) for 6 h in the presence or absence of 1 μM THZ1 and 10 μM A-92 as indicated (B, C). Following indicated treatments, resulting cell lysates were subjected to SDS-
PAGE followed by immunoblotting using the antibodies shown. Quantified values are the mean ± S.E.M. from three independent experiments. *P < 0.05 between
indicated bar values. NS, not significant.
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CDK12 [29]. To test whether the effects of THZ-1 were a consequence
of CDK12 inhibition, we utilised THZ531; a highly selective covalent
inhibitor of CDK12 and CDK13 (IC50 158 nM and 69 nM, respectively)
that has very weak action on CDK7 (IC50 8.5 μM) [57]. Fig. 10B shows
that unlike THZ-1, THZ531 had no impact on the adaptive increase in
Me-AIB uptake when HeLa cells were subject to AA withdrawal ex-
cluding any involvement of CDK12 or CDK13 in the AAR regulating
System A.
4. Conclusions
Like many cell stresses (e.g. UV radiation, heat shock, osmotic
stress), AA insufficiency is known to impact negatively upon cell growth
and survival and modulates signalling pathways that allow adaptation
to environmental cues affecting normal cellular function. The GCN2-
ATF4 pathway is one component of the ISR that enables cells to deal
with nutrient-induced stress. Cellular restriction or deprivation of AAs
results in GCN2 activation and this induces phosphorylation of eIF2α
leading, on the one hand, to a global suppression of mRNA translation
and, on the other, translation and transcription of ATF4-regulated genes
that facilitate adaptation and recovery of cells to AA deficiency. In
addition, GCN2 has also been implicated in cell cycle arrest via its
ability to selectively upregulate, through phosphorylation of eIF2α, the
translation of a cell cycle inhibitor, p21Cip1, which subsequently re-
strains G1/S transition [31]. In this regard, GCN2 functions as a novel
checkpoint suppressing cellular proliferation under circumstances of
nutrient insufficiency and, as such, this allows cells to survive nu-
tritionally unfavourable conditions. These latter observations under-
score the inter-dependent relationship between components of the ISR
and cell cycle checkpoint controls, which have previously also been
highlighted for other stress-activated kinases such as SAPK/JNK and
p38 MAP kinases [44].
The genomic-driven increase in SNAT2/System A transport activity
seen in cells upon extracellular AA limitation represents a well-estab-
lished component of the ISR [17,22,32] that is crucially dependent
upon activation of the GCN2/ATF4 pathway. Our initial observations
suggested that GSK3 may be a component of this ISR; a possibility
supported by a study in cells of neuronal lineage which presented
evidence that expression of CHOP, a transcription factor involved in the
ISR, was regulated in a GSK3-dependent manner [38]. However, it is
noteworthy that the proposed involvement of GSK3 in this study was
based on using inhibitors of the indirubin and paullone class that are
also known to target members of the CDK family [3], therefore further
validation that GSK3 is involved in the ER stress response triggering
CHOP expression seems warranted. Indeed, a very recent study in
vascular smooth muscle cells demonstrated that whilst CHOP expres-
sion in response to saturated fatty acid-induced ER stress was repressed
by kenpaullone (a GSK3/CDK inhibitor), this inhibitor-sensitive in-
duction of CHOP was, in fact, mediated by CDK9 [52], which, like
CDK7, also participates in the regulatory control of RNA transcripts
generated by RNA polII [48].
Significantly, the current work identifies CDK7 as a novel compo-
nent of the ISR mediating the upregulation of SNAT2 expression/
function in cells subject to AA starvation. Our studies reveal, for the
first time, that AA withdrawal promotes an increase in CDK7 activity
and that this is associated with enhanced Ser 5 phosphorylation of the
CTD of RNAPII that may help promote greater transcription of target
genes involved in stress adaptation. It is currently unclear whether the
SNAT2 gene itself is a downstream target of the increased CDK7 activity
or if its upregulation is a secondary consequence of the kinase targeting
expression of the ATF4 gene. Since translation of ATF4 mRNA tran-
scripts would be preferentially enhanced under circumstances when
eIF2α is phosphorylated this would be expected to subsequently pro-
mote expression of ATF4-regulated genes such as CHOP, ATF3 and
SNAT2. Precisely how CDK7 is activated in response to AA deprivation
is unclear but, since CDK7 mediated phosphorylation of the CTD of
RNAPII is sensitive to A-92, our findings would imply that GCN2 acti-
vation is mechanistically linked to the downstream activation of CDK7.
We accept that global changes in the cellular level of Ser 5 phosphor-
ylation within the CTD of RNAPII may not necessarily correlate with
changes taking place at the regulatory region(s) of target genes where
the polymerase acts and, consequently, there is value in future studies
trying and establish how genetic or pharmacological modulation of
CDK7 might affect pSer5 RNAPII phosphorylation within the promoter
regions of target genes. We also currently do not know whether the
GCN2-CDK7 link is direct or indirect, but there is growing evidence in
the literature that substrates other than eIF2α can mediate the stress-
induced effects of GCN2 in both yeast and mammalian cells [39].
Whether GCN2 physically interacts with CDK7 or can influence phos-
phorylation of the latter on either one of its two T-loop residues (Ser164
or Thr170) that are crucial for the kinase to form a stable complex with
cyclin H and MAT1 in vivo and for its CTD kinase activity [30] remain
interesting, but open questions for future investigation.
Fig. 10. Effects of expressing a doxycycline-in-
ducible drug-resistant CDK7 on System A adaptation
in response to AA withdrawal.
HeLa S3 cells stably expressing doxycycline-in-
ducible FLAG-WT CDK7 or FLAG-C132S CDK7 con-
structs (or empty vector (EV)) were treated with (+)
or without (−) doxycycline (2 μg/ml) for 24 h.
Resulting cell lysates were subjected to SDS-PAGE
and immunoblotted using the antibodies indicated
(A). Alternatively, doxycycline treated cells were
deprived of amino acids (−) or not (+) for 6 h in the
presence or absence of 1 μM THZ-1 prior to mea-
surement of Me-AIB uptake rates (A). In addition,
wild type HeLa cells were starved of amino acids (−)
or not (+) for 6 h in the presence or absence of 1 μM
THZ-1 and the indicated concentrations of THZ531
(B). Quantified values are presented as the
mean ± S.E.M. (n= 3). *, P < 0.05; NS, not sig-
nificant relative to corresponding amino acid con-
taining control unless otherwise indicated.
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